Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...
Keytruda Qlex is now FDA-approved for subcutaneous use in patients 12 and older with solid tumors, offering an alternative to IV administration. Subcutaneous administration can improve patient ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
DIPCAN, a multidimensional approach to precision oncology: Harnessing genomic, clinical, pathological and radiographic data to advance personalized cancer treatment. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results